Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SCYX

SCYNEXIS Q3 2025 Earnings Results & Report

SCYNEXIS logo
$3.33 -0.08 (-2.35%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$3.32 -0.01 (-0.30%)
As of 11/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$1.36 versus the -$1.68 consensus estimate, while revenue of $334 thousand topped the $148 thousand estimate by $186.00 thousand.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

SCYNEXIS EPS Results

Actual EPS
-$1.36
Consensus EPS
-$1.68
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

SCYNEXIS Revenue Results

Actual Revenue
$334 thousand
Expected Revenue
$148 thousand
Beat/Miss
Beat by +$186.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

SCYNEXIS's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
SCYNEXIS's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

SCYNEXIS Q3 2025 Earnings FAQ

SCYNEXIS (NASDAQ:SCYX) reported earnings of -$1.36 per share for Q3 2025, beating the consensus estimate of -$1.68. The report was announced on Wednesday, November 5, 2025.

SCYNEXIS reported revenue of $334 thousand for Q3 2025, against a consensus estimate of $148 thousand.

SCYNEXIS Earnings Headlines

FY2026 EPS Forecast for SCYNEXIS Reduced by Analyst
November 12 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192863
SCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program Advances
November 10 at 4:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190292
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
 |  Crypto 101 Media (Ad)
SCYNEXIS (NASDAQ:SCYX) Cut to "Sell" at Wall Street Zen
November 10 at 2:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189009
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396422/0/en/scynexis-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391192/0/en/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference.html
See More SCYNEXIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email.

About SCYNEXIS

SCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis. It is also approved to reduce the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females. Unlike azole antifungals, ibrexafungerp belongs to a different structural class and is being developed to address infections involving fungi that may be resistant to existing treatments.

The company is also evaluating ibrexafungerp for additional indications, including certain invasive fungal infections, and has pursued opportunities to expand the product’s use through clinical development and commercial collaborations. SCYNEXIS is headquartered in Jersey City, New Jersey, and its principal commercial focus has been the United States, where BREXAFEMME is marketed for approved indications.

View SCYNEXIS Profile
Earnings Tools